Overactive BladderNCT07513363
The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency
A study testing Urotherapy in people with Overactive Bladder and Vitamin D Deficiency, run by Tarik Emre Sener at 1 site in Turkey (Türkiye).
Trial summary
The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency. Read more about this study
- Who is it for?
- Ages Up to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Overactive Bladder, Vitamin D Deficiency
- What is being tested?
- Urotherapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 May 2026to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)
Who cannot join
- Neurological diseases
- Malignancy
- Active urinary tract infections
- Anatomical bladder anomalies
- History of prior OAB treatment/urological surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Marmara University School of Medicine Urology Department
Pendik, Istanbul, 34100
Cagri Akin Sekerci, 05344525700, cagri_sekerci@hotmail.com
About this study
Official title: The Role of Urinary RhoA, NGF, and BDNF Levels in Diagnosis and Follow-up in Children With Overactive Bladder and Vitamin D Deficiency.
The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.
- Conditions
- Overactive Bladder, Vitamin D Deficiency
- Being tested
- Urotherapy
- Medical subject headings
- Urinary Bladder, Overactive, Vitamin D Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UrotherapyBehavioural
Diagnosis and first-line treatment (urotherapy) will be conducted per European Association of Urology (EAU) guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Overactive Bladder Group | Active comparator | Not described Receives: Behavioral: Urotherapy |
| Healthy Group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Urinary Biomarker Levels: * Quantitative measurement of urinary RhoA, NGF (Nerve Growth Factor), and BDNF (Brain-Derived Neurotrophic Factor) levels using the ELISA method.
Measured: One year
Secondary outcomes (1)
Clinical Symptom Improvement: * Reduction in LUTS (Lower Urinary Tract Symptoms) based on standardized voiding dysfunction symptom scores.
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start1 May 2026 (estimated)
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overactive BladderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tarik Emre Sener
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Tarik Emre Sener, Marmara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07513363
- Sponsor's protocol ID
- MAR.UAD.0031
- Status last verified
- Apr 2026
- First submitted
- 1 Apr 2026
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Urinary RhoA, NGF, and BDNF Levels in Diagnosis and Follow-up in Children With Overactive Bladder and Vitamin D Deficiency.
- ClinicalTrials.gov ID
- NCT07513363
- Acronym / sponsor ID
- MAR.UAD.0031
- Conditions
- Overactive Bladder, Vitamin D Deficiency
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Tarik Emre SenerUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Overactive Bladder Group | Active comparator | Behavioral: Urotherapy |
| Healthy Group | No intervention | – |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)
Key exclusion criteria (5 listed)
- Neurological diseases
- Malignancy
- Active urinary tract infections
- Anatomical bladder anomalies
- History of prior OAB treatment/urological surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| UrotherapyDiagnosis and first-line treatment (urotherapy) will be conducted per European Association of Urology (EAU) guidelines. | Behavioural | Overactive Bladder Group |
Primary outcome
Changes in Urinary Biomarker Levels: * Quantitative measurement of urinary RhoA, NGF (Nerve Growth Factor), and BDNF (Brain-Derived Neurotrophic Factor) levels using the ELISA method.
Time frame: One year
1 secondary outcome
Clinical Symptom Improvement: * Reduction in LUTS (Lower Urinary Tract Symptoms) based on standardized voiding dysfunction symptom scores.
Time frame: One year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Overactive Bladder
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Urotherapy in people with Overactive Bladder and Vitamin D Deficiency, run by Tarik Emre Sener at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hamza Tunahan Midilli (905449695848, hamzamidilli@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Urinary Biomarker Levels: * Quantitative measurement of urinary RhoA, NGF (Nerve Growth Factor), and BDNF (Brain-Derived Neurotrophic Factor) levels using the ELISA method. (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.